Nuvelo (NASDAQ:NUVO) was formed in 2003 from the merger of Hyseq, Inc. and Variagenics, Inc. with Hyseq in the lead role. With a series of post IPO financings to support the firm's expanding capabilities the firmhad grwon the 250 people but in late 2008 the firm eventually was acquired by ARCA Biopharma in a reverse merger. Organized around DNA array technology, Hyseq had engaged in R&D of novel biopharmaceutical protein-based products for the treatment of human disease from the Company's collection of proprietary genes discovered using its high-throughput signature-by-hybridization platform. With several product candidates to treat various diseases and medical conditions including cardiovascular disease and oncolog, the Company's signature-by-hybridization platform, which is related to its proprietary sequencing-by-hybridization technology, gave it a significant advantage in discovering novel, rarely expressed genes. Nuvelo possessed an important proprietary database of full-length human gene sequences that effectively enabled a raft of collbaorations with major and mid-sized corporations and leading academic and research institutions.
